Prospective Study of Serum Marker LncRNA RP5-977B1 in Pulmonary Nodules

Launched by AFFILIATED CANCER HOSPITAL & INSTITUTE OF GUANGZHOU MEDICAL UNIVERSITY · Jul 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a specific serum marker called LncRNA RP5-977B1 to see if it can help doctors determine whether pulmonary nodules (small growths in the lung) are benign (non-cancerous) or malignant (cancerous). The goal is to improve the diagnosis of these nodules using both this new marker and existing protein tumor markers, and to evaluate how effectively they can distinguish between benign and malignant nodules based on further testing.

To participate in this trial, you need to be between the ages of 15 and 75 and have had a pulmonary nodule detected through imaging that is planned to be surgically removed for testing. It's important that you have good blood, liver, and kidney function. However, if you have a history of cancer, serious health issues, or have received certain treatments recently, you may not be eligible. If you join the study, you can expect to have your blood tested, and the results will help improve the understanding and diagnosis of lung nodules, which could ultimately lead to better patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pulmonary nodules were detected by imaging and surgically resected.
• • Age 15-75 years old.
• • Surgery or puncture is to be performed for pathological diagnosis.
• • Adequate hematological function and liver and kidney function reserve. ⑤ The sample has no hemolysis, sufficient margin, and the source record is clear and can be checked.
• Exclusion Criteria:
• • Patient samples have hemolysis, have been contaminated, have been placed for too long, have insufficient sample allowance, and record mixed samples.
• • History of malignant tumor. ③ Serious underlying diseases and complications may affect systemic treatment. ④ Can not guarantee to receive blood tests on time. ⑤ Received anti-tumor Chinese medicine, immunization, chemotherapy and other treatments within 2 weeks.